"10.1371_journal.pone.0104837","plos one","2014-08-26T00:00:00Z","Malene Hornbak; Kristine Højgaard Allin; Majken Linnemann Jensen; Cathrine Juel Lau; Daniel Witte; Marit Eika Jørgensen; Annelli Sandbæk; Torsten Lauritzen; Åsa Andersson; Oluf Pedersen; Torben Hansen","The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; School of Pharmaceutical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Steno Diabetes Center A/S, Gentofte, Denmark; Section for Social and Clinical Pharmacy, Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Research Centre for Prevention and Health, Capital Region of Denmark, Glostrup Hospital, Glostrup, Denmark; Public Research Centre for Health, Centre for Health Studies, Strassen, Luxembourg; Department of Public Health, Section of General Practice Medicine, Aarhus University, Aarhus, Denmark; Institute of Biomedical Science, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark; Section of Molecular Diabetes & Metabolism, Institute of Clinical Research & Institute of Molecular Medicine, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark","Conceived and designed the experiments: MH MEJ DW AS TL OP TH. Performed the experiments: MH KHA MLJ CJL TH. Analyzed the data: MH KHA MLJ CJL AA. Contributed reagents/materials/analysis tools: MEJ DW AS TL OP TH. Contributed to the writing of the manuscript: MH KHA MLJ CJL DW MEJ AS TL AA OP TH.","The authors have read the journal's policy and have the following conflicts: MLJ and MEJ are employed by the Steno Diabetes Center A/S, which is a research and teaching hospital collaborating with the Danish National Health Service and owned by Novo Nordisk A/S. Additionally, TH, OP, MLJ, MEJ, CJL and DW hold shares in Novo Nordisk A/S. Finally, the ADDITION trial has been given unrestricted grants from Novo Nordisk A/S, Novo Nordisk Scandinavia AB, ASTRA Denmark, Pfizer Denmark, GlaxoSmithKline Pharma Denmark, SERVIER Denmark A/S and HemoCue Denmark A/S. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2014","08","Malene Hornbak","MH",11,TRUE,7,5,5,NA,TRUE,TRUE,TRUE,1,"9",FALSE
